Login to Your Account



Bavarian Nordic shares plunge on Prostvac phase III miss in prostate cancer

By Cormac Sheridan
Staff Writer

Friday, September 15, 2017

DUBLIN – Bavarian Nordic A/S lost half its market value Friday when an interim analysis showed that a phase III trial of its cancer vaccine, Prostvac, was not going to deliver a good result.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription